Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + whole cell pertussis + measles vaccine
- Development stage
- Unknown
- Lead developer
- Medical Research Council Unit The Gambia
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination vaccine regimen consists of the trivalent DTP (diphtheria, tetanus, and whole-cell pertussis) vaccine and the live-attenuated measles vaccine. The DTP component is an inactivated vaccine containing diphtheria and tetanus toxoids along with inactivated whole-cell *Bordetella pertussis*. The measles component utilizes the live-attenuated Edmonston-Zagreb strain. This specific combination was evaluated in clinical research conducted by the Medical Research Council Unit, The Gambia, to investigate the immunological interactions between live and killed vaccines in infants, specifically focusing on the effects on T-cell memory and innate immunity when co-administered at 9 months of age. Both vaccine components used in the Gambian study were manufactured by the Serum Institute of India.
- Other names
- DTP-MVDTP + Measles vaccineDTP-measles combination
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + whole cell pertussis + measles vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + whole cell pertussis + measles vaccine.